NewsBenzingaMAIA Biotechnology Completes Enrollment Of Patients For Part C Of Phase 2 Study Of Ateganosine Sequenced With CPI Cemiplimab To Treat Non-Small Cell Lung Cancer MAIA Biotechnology Completes Enrollment Of Patients For Part C Of Phase 2 Study Of Ateganosine Sequenced With CPI Cemiplimab To Treat Non-Small Cell Lung Cancer Benzinga 2026.10.07 12:16 (GMT+0) Open on Benzinga Other news BofA: US memory stock valuations show signs of cycle bottom, market concerns overblown BCX: Invest In Essential Resources, Collect 7% Monthly Income (NYSE:BCX) Tech stocks stumbled. Now comes a crucial week for Wall Street. UnitedHealth: My Thesis Has Played Out, I Wouldn't Chase Here (NYSE:UNH) OFG Bancorp: Risks Remain, But Not Enough To Prevent An Upgrade (NYSE:OFG) Vaxcyte: Vaccine Titan In The Making (NASDAQ:PCVX)
